$436.11
0.40%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US5588681057
Symbol
MDGL

Madrigal Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Madrigal Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
87%
Hold
9%
Sell
4%

Madrigal Pharmaceuticals, Inc. Price Target

Target Price $448.29
Price $436.11
Potential
Number of Estimates 18
18 Analysts have issued a price target Madrigal Pharmaceuticals, Inc. 2026 . The average Madrigal Pharmaceuticals, Inc. target price is $448.29. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 23 analysts: 20 Analysts recommend Madrigal Pharmaceuticals, Inc. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Madrigal Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Madrigal Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 180.13 890.07
394.13%
EBITDA Margin -275.79% -41.59%
84.92%
Net Margin -258.64% -26.63%
89.70%

17 Analysts have issued a sales forecast Madrigal Pharmaceuticals, Inc. 2025 . The average Madrigal Pharmaceuticals, Inc. sales estimate is

$890m
Unlock
. This is
72.64% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$953m 84.92%
Unlock
, the lowest is
$817m 58.42%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $180m
2025
$890m 394.13%
Unlock
2026
$1.4b 57.74%
Unlock
2027
$2.1b 49.15%
Unlock
2028
$2.9b 37.30%
Unlock
2029
$3.8b 32.35%
Unlock
2030
$4.4b 14.95%
Unlock
2031
$4.4b 0.30%
Unlock
2032
$4.6b 6.33%
Unlock

6 Analysts have issued an Madrigal Pharmaceuticals, Inc. EBITDA forecast 2025. The average Madrigal Pharmaceuticals, Inc. EBITDA estimate is

$-370m
Unlock
. This is
20.03% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-333m 7.93%
Unlock
, the lowest is
$-396m 28.55%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-497m 30.74%
2025
$-370m 25.49%
Unlock
2026
$-73.5m 80.15%
Unlock
2027
$429m 683.38%
Unlock

EBITDA Margin

2024 -275.79%
2025
-41.59% 84.92%
Unlock
2026
-5.23% 87.42%
Unlock
2027
20.48% 491.59%
Unlock

19 Madrigal Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Madrigal Pharmaceuticals, Inc. net profit estimate is

$-237m
Unlock
. This is
15.92% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-132m 53.07%
Unlock
, the lowest is
$-332m 17.88%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-466m 24.69%
2025
$-237m 49.13%
Unlock
2026
$44.1m 118.62%
Unlock
2027
$445m 907.39%
Unlock
2028
$947m 112.87%
Unlock
2029
$1.6b 73.57%
Unlock
2030
$2.0b 19.00%
Unlock
2031
$2.3b 17.02%
Unlock
2032
$2.0b 11.27%
Unlock

Net Margin

2024 -258.64%
2025
-26.63% 89.70%
Unlock
2026
3.14% 111.79%
Unlock
2027
21.24% 576.43%
Unlock
2028
32.92% 54.99%
Unlock
2029
43.18% 31.17%
Unlock
2030
44.70% 3.52%
Unlock
2031
52.46% 17.36%
Unlock
2032
43.78% 16.55%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -21.90 -10.67
9.55% 51.28%
P/E negative
EV/Sales 10.16

19 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast for earnings per share. The average Madrigal Pharmaceuticals, Inc. EPS is

$-10.67
Unlock
. This is
15.92% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-5.95 53.11%
Unlock
, the lowest is
$-14.95 17.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-21.90 9.55%
2025
$-10.67 51.28%
Unlock
2026
$1.99 118.65%
Unlock
2027
$20.01 905.53%
Unlock
2028
$42.60 112.89%
Unlock
2029
$73.94 73.57%
Unlock
2030
$87.99 19.00%
Unlock
2031
$102.96 17.01%
Unlock
2032
$91.36 11.27%
Unlock

P/E ratio

Current -34.37 231.52%
2025
-40.88 18.95%
Unlock
2026
219.55 637.06%
Unlock
2027
21.79 90.08%
Unlock
2028
10.24 53.01%
Unlock
2029
5.90 42.38%
Unlock
2030
4.96 15.93%
Unlock
2031
4.24 14.52%
Unlock
2032
4.77 12.50%
Unlock

Based on analysts' sales estimates for 2025, the Madrigal Pharmaceuticals, Inc. stock is valued at an EV/Sales of

10.16
Unlock
and an P/S ratio of
10.92
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 17.54 94.20%
2025
10.16 42.08%
Unlock
2026
6.44 36.60%
Unlock
2027
4.32 32.95%
Unlock
2028
3.15 27.17%
Unlock
2029
2.38 24.44%
Unlock
2030
2.07 13.01%
Unlock
2031
2.07 0.30%
Unlock
2032
1.95 5.95%
Unlock

P/S ratio

Current 18.85 94.86%
2025
10.92 42.08%
Unlock
2026
6.92 36.60%
Unlock
2027
4.64 32.95%
Unlock
2028
3.38 27.17%
Unlock
2029
2.55 24.44%
Unlock
2030
2.22 13.01%
Unlock
2031
2.23 0.30%
Unlock
2032
2.10 5.95%
Unlock

Current Madrigal Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
TD Cowen
Locked
Locked
Locked Aug 26 2025
JMP Securities
Locked
Locked
Locked Aug 20 2025
UBS
Locked
Locked
Locked Aug 12 2025
Canaccord Genuity
Locked
Locked
Locked Aug 06 2025
B. Riley Securities
Locked
Locked
Locked May 02 2025
UBS
Locked
Locked
Locked May 02 2025
Canaccord Genuity
Locked
Locked
Locked May 02 2025
Analyst Rating Date
Locked
TD Cowen:
Locked
Locked
Aug 26 2025
Locked
JMP Securities:
Locked
Locked
Aug 20 2025
Locked
UBS:
Locked
Locked
Aug 12 2025
Locked
Canaccord Genuity:
Locked
Locked
Aug 06 2025
Locked
B. Riley Securities:
Locked
Locked
May 02 2025
Locked
UBS:
Locked
Locked
May 02 2025
Locked
Canaccord Genuity:
Locked
Locked
May 02 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today